Innate Pharma S.A.

Good morning, everyone. My name is Juan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma first quarter 2022 business update. All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, followed by number one on your telephone keypad. If you would like to withdraw your question, please press star, followed by number two. I will now introduce to Mr. Henry Wheeler, Head of Investor Relations. Please, Mr. Wheeler, go ahead.

Thank you. Good morning and good afternoon and welcome, everyone. This morning, Enate issued a press release providing a business update for our first quarter 22 results. We look forward to highlighting the progress made during the quarter as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website. On slide two, before we start, I would like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risk and uncertainties that may cause actual results to differ from those forecasted. On slide three, on today's call, we will be joined by Mwanda Bajubi, our Chief Executive Officer, who will then hand over to Joyce Nkarakanal, EVP and Chief Medical Officer, and Yanis Morel, EVP of Business Development and Product Portfolio Strategy. And we will also have our CFO, Frederick Lombard, on for Q&A. Monda, I'll now hand over to you.

Thank you, Henry. Good morning, good afternoon, everyone, and thank you for joining this call. Please move to slide four and let me first start by reminding you our strategy. Our strategy centers around three key priorities where we look to drive value from our early R&D efforts for later stage partnerships, whether it makes sense to do so. First, we look to create near-term value driven by our lead proprietary candidate, LakutaMap, which is in development for TCL Informa. We did open an all-channels cohort in Microsys Honduras in the Telemach trial and also initiated two trials in the larger indication of TCL Informa. Second, we continue to show our planning and create longer-term value leveraging our antibody engineering capabilities to develop innovative molecules with a primary focus on our multi-specific NKC-Engager platform called ANCET. Sanofi has the most advanced ANCET in the clinic and we are nearing the clinic with the others. On the ANGEN pathway, we have the phase one underway for our anti-CD73 APH5301, performed in partnership with the Pauli Calmet Institute, the Antiquities Center here in Marseille. And we are in further discussion with AstraZeneca on the next step for our anti-CD39 APH5301. Last but not least, we continue to build a strong and sustainable foundation for our business, leveraging the various partnerships between unit pharma and industry, but also with academia. Our focus here is to leverage the value of our product as much as possible. We want to make sure that if we can gain valuable competency via a partner agreement, we will consider that in our development plans for the product. This will not only validate our science, but also offer capital we can invest to advance our early portfolio. And building on this On this last pillar, if you can move to slide five, you can see the milestone summary for Mona Lisa now. We were very pleased to announce a couple of days ago that we had received a further milestone of 50 million US dollars for the dosing of the first patient in the Phase 3 trial, Pacific Night, which is AstraZeneca's registration of trial in Phase 3 unrejectable lung cancer. This milestone further strengthened our company's cash position. We remind you that we have potentially up to another 400 million in development and regulatory milestones, and 425 million in sales milestones to come. Before I hand over to Gerson, please move to slide six, which is an overview of the pipeline, and it shows how we have translated our science into a robust portfolio of proprietary and partner assets. It also illustrates how we are executing against our strategy with our lead proprietary asset, Takutamab, supported by personal and earlier stage products, in particular from our NKCL Engager NK platform. We're also busy to see the progress throughout the portfolio with several clinical assets continuing to progress from phase one through to registration phase three trial. And we look forward to a series of potential clinical data results and catalysts in the upcoming couple of years as our R&D engine looks to leverage our scientific know-how in order to create sustainable business. I would like now to pass the call over to Jason, who will review the progress made in our portfolio, starting with, like it or not, our most advanced proprietary assets. Jason, over to you, please.